Article

Travoprost with less toxic preservative causes less ocular surface toxicity

In a pooled dataset, the fixed combination of 0.2% brimonidine/0.5% timolol (Combigan, Allergan) showed greater reductions in IOP and a better tolerability profile than another combination agent, 2.0% dorzolamide/0.5% timolol (Cosopt, Merck). The twin advantages of greater pressure lowering and greater tolerability could help guide clinicians in choosing which therapy to choose when the initial treatment has not resulted in adequate improvement.

Key Points

Singapore-In a pooled data set, the fixed combination of 0.2% brimonidine/0.5% timolol (Combigan, Allergan) showed greater reductions in IOP and a better tolerability profile than another combination agent, 2.0% dorzolamide/0.5% timolol (Cosopt, Merck).

The directed phase IV study was designed to follow up more rigorously on the trends identified in previous studies, according to Donald R. Nixon, MD, senior consultant, Department of Ophthalmology, Royal Victoria Hospital, Barrie, Ontario.

Two previous studies (Combigan Early Experience Data Trial, parts I and II) compared those fixed combination agents, and both indicated that the brimonidine/timolol combination was more advantageous. Both studies, although having a large number of participants, were limited by being unmasked or open label.

Clinicians in Canada have had access to the brimonidine/timolol combination for more than 2 years, and the agent met early acceptance, Dr. Nixon noted. He explained that use of the combination offered more benefits than use of two separate agents because of the dual mechanism of action and greater convenience of single dosing, which enhanced patient compliance.

In Canada, if initial monotherapy with a prostaglandin analog fails to achieve an adequate reduction in IOP, the accepted protocol is to switch to another prostaglandin analog prior to adding another agent, such as a drug from a different category or a fixed combination.

"However they get there, in Canada, a significant percentage of patients end up being treated with a fixed-combination medication in conjunction with a prostaglandin analog, so this study really represents clinical practice," Dr. Nixon said. What resulted from the desire to obtain more scientifically valid data on the two combination agents was a pair of randomized, investigator-masked, 3-month parallel comparison studies of efficacy and tolerability. The studies were conducted at 10 sites in Canada with identical protocols.

In a poster presentation at the World Glaucoma Congress meeting, Dr. Nixon released pooled data from the studies, which enrolled 180 patients with ocular hypertension or open-angle glaucoma who required additional lowering of their IOP levels.

A small percentage of the patients were naïve to therapy, and they were randomly assigned to either of the two combination agents. Most patients, however, had preexisting disease and were receiving therapy such as beta-blockers, alpha-adrenergics, or carbonic anhydrase inhibitors. After wash-out, patients were randomly assigned to a combination medication. A third group consisted of patients who may have been taking a prostaglandin analog and another medication. All medication was washed out except the prostaglandin analog, then patients were randomly assigned to one of the combination therapies. Ultimately, 101 patients were assigned to a fixed combination and 79 to prostaglandin analog.

"The end result at 3 months was that there was a statistically significant advantage in pressure lowering effect for brimonidine/ timolol over dorzolamide/timolol," Dr. Nixon said. "The other thing that was quite interesting [was] that if you take a look at the subgroup that started with a prostaglandin analog and then brimonidine/timolol was initiated, there was a very impressive reduction in pressure, suggesting that the combination of the prostaglandin analog with the brimonidine/timolol showed a significant therapeutic advantage."

In another important outcome of the study, the brimonidine/timolol combination agent also was rated more highly on a patient tolerability questionnaire. The survey was administered at 1 month to assess symptoms of stinging, burning, and unusual taste on a scale of 0 to 5 and was scored independently.

"There was statistically less stinging, less burning, and less bad taste with the brimonidine/timolol," Dr. Nixon said. That advantage persisted over the duration of the study, he added.

The twin advantages of greater pressure lowering and greater tolerability could help guide clinicians on which therapy to choose when the initial treatment has not resulted in adequate improvement, Dr. Nixon continued.

A paper about the study is being submitted for publication.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.